# Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

> **NCT05411380** · PHASE2 · UNKNOWN · sponsor: **wang shusen** · enrollment: 73 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tucidinostat
- **DRUG:** Capecitabine
- **DRUG:** Endocrine Therapy

## Key facts

- **NCT ID:** NCT05411380
- **Lead sponsor:** wang shusen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-03
- **Primary completion:** 2024-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411380, "Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05411380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*